amr industry alliance
The AMR Industry Alliance is one of the largest private sector coalitions set up to provide sustainable solutions to curb antimicrobial resistance, with over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations joining forces.
read moreWe drive and measure the life-sciences industry progress to curb antimicrobial resistance in four different areas:
shared goals
We are uniting efforts to reduce the development of antimicrobial resistance, invest in R&D to meet public health needs and improve access to antibiotics, vaccines and diagnostics.
progress report
In 2018, the Alliance published its first progress report that provides unique insights into the practical steps its members are taking to respond to AMR. The findings of the report illustrate both the challenges the healthcare sector faces in tackling AMR and how the industry is essential to winning this battle.
in action
Our case studies provide snap-shots from across the life-sciences industry, share information on the tangible steps we are taking to invest in new research to develop new antibiotics and vaccines, prevent infection ,and improve appropriate use of antibiotics.
latest news
AMR Industry Alliance Round-Up, Issue No.3, November 2019
Welcome to the third issue of the Alliance Round-Up – written for more than 100 biotech, diagnostic, generic and R&D pharma companies that are members of the AMR Industry Alliance, as well as p...
Read more
AMR Industry Alliance Round-Up, Issue No.2, September 2019
Welcome to the second issue of the Alliance Round-Up – written for more than 100 biotech, diagnostic, generic and R&D pharma companies that are members of the AMR Industry Alliance, as well as...
Read more
New brochure to discover the AMR Industry Alliance in 2 minutes
Representing more than 100 biotechnology, diagnostics, generics and research-based pharmaceutical companies and associations, the AMR Industry Alliance is one of the largest private sector coalitions...
Read moreamr in numbers
AMR Impact
Life-sciences at the forefront of the battle against AMR
Development of National Action Plans
R&D
Biotechs
Diagnostics
from the blog
US FDA report finds economic forces at the root of generic antibiotic shortages
Generic antibiotics underpin recommended prescribing guidance for most infections, accounting for between 80% and 90% of prescriptions in primary healthcare worldwide. However, increasing costs and inadequate incentives for quality-assured manufacturers is feeding through into shortages of these ess...
Read more view all
